Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among […]
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among […]
